As of October 2026, the newest FDA-approved sleep apnea treatments are Zepbound, the first medicine approved for sleep apnea, and two newer nerve stimulation implants that join Inspire. A nightly pill called AD109 is still under FDA review and is not approved. CPAP remains the standard first treatment for most adults.
What is new in sleep apnea treatment?
For many years, the main choices for obstructive sleep apnea were CPAP, oral appliances, surgery and weight loss. In the last few years, that list has grown. Some new options are approved by the FDA and available now. Others are still being tested in clinical trials.
This guide keeps those two groups apart. An approved treatment has passed FDA review for a specific use. An investigational treatment has not. Research news can make a treatment sound ready before it is, so the date and the FDA status matter.
The first medicine approved for sleep apnea
In December 2024, the FDA approved Zepbound (tirzepatide) for moderate to severe obstructive sleep apnea in adults with obesity. It was the first medicine approved to treat sleep apnea. It is a shot given once a week and is used along with a lower-calorie diet and more physical activity.[1]
Zepbound helps people lose weight, and less weight can mean less pressure on the airway at night.[2] It is not approved for sleep apnea in people without obesity. Common side effects include nausea, diarrhea, vomiting and constipation.[1] Some people use it together with CPAP rather than in place of it. To learn how weight affects breathing during sleep, see sleep apnea and weight loss.
Nerve stimulation implants: more than one choice now
Nerve stimulation implants send a gentle signal to the nerve that moves the tongue, so the tongue does not fall back and block the airway during sleep. There are now three FDA-approved choices:
- Inspire system — FDA-approved since 2014, the first of the three.[3] It stimulates the tongue nerve on one side, timed with your breathing. An implanted battery powers it, and you turn it on with a small remote at bedtime. It is approved for adults 18 and older (and some teens 13 and older with Down syndrome) with an AHI of 15 to 100.[4] Our Inspire therapy guide explains how it works and who qualifies.
- Genio system — approved in August 2025. It stimulates the tongue nerve on both sides. The implant has no battery inside; a small part worn under the chin at night powers it. It is approved for adults 22 and older.[5]
- aura6000 system — approved in March 2026. It stimulates the tongue nerve at a point closer to where the nerve starts. It is approved for adults who failed or could not use standard treatments such as CPAP.[6]
Genio and aura6000 are approved for moderate to severe sleep apnea with an apnea-hypopnea index (AHI) of 15 to 65[5][6]; Inspire's approval goes up to an AHI of 100.[4] Each device has its own rules about who qualifies, and doctors are still learning how they compare. For an overview of all implants, read implantable sleep apnea devices.
A sleep apnea pill still under FDA review
AD109 is a pill taken at bedtime. It combines two drugs, aroxybutynin and atomoxetine. The goal is to help the throat muscles stay firm during sleep so the airway stays open. The company has proposed the brand name Oxnimbi.[7]
In two large studies, adults who took AD109 had fewer breathing pauses than those who took a placebo (a pill with no medicine). Some people stopped taking it because of side effects such as dry mouth, trouble sleeping, nausea and trouble starting to urinate.[8]
The FDA accepted the application for review in July 2026 and expects to decide by February 28, 2027.[9] As of October 2026, AD109 is not FDA-approved. It may or may not be approved, and its final label could differ from what is described here.
Other ideas still in research
- Other medicines — Scientists are testing other drugs that target the throat muscles or breathing control. These are investigational.
- Matching treatment to the person — Sleep apnea has different causes in different people. Researchers are studying ways to pick a treatment based on why a person's airway closes.
- Newer device versions — Device makers are working on updated implants. A new version is not approved until the FDA says so.
- Daytime tongue training — One mouthpiece device that trains the tongue muscle while awake was authorized by the FDA in 2021 for snoring and mild sleep apnea in adults. It is not for moderate or severe sleep apnea.[10]
How to tell approved from investigational
- Look for the FDA status — "Approved" means the FDA reviewed it for a specific use and group of people. "In trials" or "under review" means it is not approved yet.
- Check who it is for — An approval often covers only some people, such as adults with obesity or adults who cannot use CPAP.
- Check the date — Treatment news changes quickly. Look for when the news was written.
- Ask about clinical trials — Trials are listed at ClinicalTrials.gov. Your doctor can help you decide if one makes sense for you.
What to do today and when to see a sleep specialist
You do not need to wait for a future treatment. Proven options work well for many people today. If CPAP has been hard for you, read about alternatives to CPAP and bring your questions to your next visit.
See a sleep specialist if you:
- Snore loudly or stop breathing in your sleep — especially if someone has seen you gasp or choke at night.
- Feel very sleepy during the day — such as dozing while driving or at work.
- Struggle with CPAP — a sleep specialist can adjust your setup or review other options.
- Want to know if a new treatment fits you — an updated sleep study may be needed first.
Sleep apnea care at Teddy Bear Pediatrics & Sleep Medicine
Dr. Minal Patel is board-certified in both pediatrics and sleep medicine. The practice offers in-lab and home sleep studies, CPAP and BiPAP therapy, Inspire evaluation and CBT-I for insomnia. Medicaid and CHIP are accepted for sleep medicine patients. The office is open Monday to Friday, 8:30 to 5:00, and is accepting new patients by appointment (no walk-ins).
References
- U.S. Food and Drug Administration. FDA approves first medication for obstructive sleep apnea. December 20, 2024. fda.gov
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193-1205. PMID: 38912654. DOI: 10.1056/NEJMoa2404881
- U.S. Food and Drug Administration. Premarket approval P130008: Inspire Upper Airway Stimulation System. Approved April 30, 2014. accessdata.fda.gov
- U.S. Food and Drug Administration. Summary of safety and effectiveness data, PMA P130008/S090: Inspire Upper Airway Stimulation System. Approved June 8, 2023. accessdata.fda.gov
- U.S. Food and Drug Administration. Premarket approval P240024: Genio System 2.1. Approved August 8, 2025. accessdata.fda.gov
- U.S. Food and Drug Administration. Premarket approval P250013: aura6000 system. Approved March 18, 2026. accessdata.fda.gov
- Apnimed, Inc. Apnimed reports second quarter 2026 financial results and provides corporate update. Form 8-K, Exhibit 99.1. September 8, 2026. sec.gov
- Strollo PJ Jr, Farkas R, Taranto-Montemurro L, et al. Aroxybutynin and atomoxetine (AD109) for obstructive sleep apnea: a randomized phase 3 trial (SynAIRgy). Am J Respir Crit Care Med. 2026;212(7):1569-1584. PMID: 42148495. DOI: 10.1093/ajrccm/aamag215
- Apnimed, Inc. Apnimed announces FDA acceptance of New Drug Application for AD109, an investigational oral pill to treat adults with obstructive sleep apnea (OSA). Press release. July 14, 2026. biospace.com
- U.S. Food and Drug Administration. De Novo DEN200018: eXciteOSA. Granted February 5, 2021. accessdata.fda.gov
